Cancer Statistics, 2004

Jemal, A.; Tiwari, R. C.; Murray, T.; Ghafoor, A.; Samuels, A.; Ward, E.; Feuer, E. J.; Thun, M. J.

doi:10.3322/canjclin.54.1.8

Cited by 3,984Global Cancer Incidence and ScreeningColorectal Cancer Screening and DetectionEconomic and Financial Impacts of Cancer

Cancer Statistics, 2004

Open access

Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., Thun, M. J.·2004·CA: A Cancer Journal for Clinicians

DOI 10.3322/canjclin.54.1.8

Open this paper in CoChat — free account

Abstract

Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival rates based on incidence data from the National Cancer Institute and mortality data from the National Center for Health Statistics. Incidence and mortality rates are age standardized to the 2000 US standard million population. A total of 1,368,030 new cancer cases and 563,700 deaths are expected in the United States in 2004. Incidence rates stabilized among men from 1995 through 2000 but continued to increase among females by 0.4% per year from 1987 through 2000. Mortality rates have decreased by 1.5% per year since 1992 among men, but have stabilized from 1998 through 2000 among women. Cancer death rates continued to decrease from the three major cancer sites in men (lung and bronchus, colon and rectum, and prostate) and from female breast and colorectal cancers in women. In analyses by race and ethnicity, African-American men and women have 40% and 20% higher death rates from all cancers combined compared with White men and women, respectively. Cancer incidence and mortality rates are lower in other racial and ethnic groups than in Whites and African Americans for all sites combined and for the four major cancer sites. However, these groups generally have higher rates for stomach, liver, and cervical cancers than do Whites. Furthermore, minority populations are more likely to be diagnosed with advanced stage disease than are Whites. Progress in reducing the burden from cancer can be accelerated by applying existing cancer control knowledge into practice among all segments of the population.

Integrity signals

Registry

Crossref · 10.3322/canjclin.54.1.8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cigarette smoking causes an estimated 85% to 90% of lung cancer deaths.
“Cigarette smoking causes an estimated 85% to 90% of lung cancer deaths.”
From Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association (2004) · cites this paper as [25]
Among cancers caused by smoking, the strongest association is with lung cancer, the most common type of fatal cancer among both men and women in the United States.
“Among these, the strongest association is with lung cancer, the most common type of fatal cancer among both men and women in the United States.”
From Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association (2004) · cites this paper as [25]
Approximately 30% of all deaths from cancer in the United States are attributable to active smoking.
“Approximately 30% of all deaths from cancer in the United States are attributable to active smoking.”
From Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association (2004) · cites this paper as [25]

Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control
Weir, H. K. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg040 · Cited by 864 · see citing works
Untitled work
(2001) · PubMed · Cited by 612 · see citing works
Cancer Statistics for African Americans
Ghafoor, A., Jemal, A., Cokkinides, V. E., Cardinez, C. J., Murray, T., Samuels, A., & Thun, M. J. (2002) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.6.326 · Cited by 549 · see citing works
Self-citation
Cancer Survival Among US Whites and Minorities
Clegg, L. X., Li, F. P., Hankey, B. F., Chu, K. C., & Edwards, B. K. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.17.1985 · Cited by 535 · see citing works
Survival of Blacks and Whites After a Cancer Diagnosis
Bach, P. B. (2002) · JAMA · doi:10.1001/jama.287.16.2106 · Cited by 514 · see citing works
Trends in Breast Cancer by Race and Ethnicity
Ghafoor, A., Jemal, A., Ward, E., Cokkinides, V. E., Smith, R. A., & Thun, M. J. (2003) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.6.342 · Cited by 450 · see citing works
Self-citation
Impact of Reporting Delay and Reporting Error on Cancer Incidence Rates and Trends
Clegg, L. X. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.20.1537 · Cited by 282 · see citing works
A New Method of Predicting US and State-Level Cancer Mortality Counts for the Current Calendar Year
Tiwari, R. C., Ghosh, K., Jemal, A., Hachey, M., Ward, E., Thun, M. J., & Feuer, E. J. (2004) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.30 · Cited by 67 · see citing works
Self-citation
Influence of Rules From the Tenth Revision of the International Classification of Diseases on U.S. Cancer Mortality Trends
Jemal, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg116 · Cited by 14 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · see citing works
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmsr043743 · Cited by 2,612 · see citing works
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377 · see citing works
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis
Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612 · see citing works
Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association
Eyre, H., Kahn, R., Robertson, R. M., the ACS/ADA/AHA Collaborative Writing Committee, ACS/ADA/AHA Collaborative Writing Committee Members, Clark, N. G., Doyle, C., Hong, Y., Gansler, T., Glynn, T., et al. (2004) · Circulation · doi:10.1161/01.cir.0000133321.00456.00 · Cited by 542 · see citing works
Self-citation
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523 · see citing works
Clinical Course of Patients With Relapsed Multiple Myeloma
Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365 · see citing works
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm374 · Cited by 356 · see citing works
Will mandatory folic acid fortification prevent or promote cancer?
Kim, Y.-I. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.5.1123 · Cited by 332 · see citing works
Molecular regulation of androgen action in prostate cancer.
Dehm, S. M., & Tindall, D. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20794 · Cited by 336 · see citing works
Phase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma Recurrence
Alberts, D. S., Martínez, M. E., Hess, L. M., Einspahr, J. G., Green, S. B., Bhattacharyya, A. K., Guillen, J., Krutzsch, M., Batta, A. K., Salen, G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji144 · Cited by 247 · see citing works
Overview of skin cancer types and prevalence rates across continents
Roky, A. H., Islam, M. M., Ahasan, A. M. F., Mostaq, M. S., Mahmud, M. Z., Amin, M. N., & Mahmud, M. A. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.08.002 · Cited by 239 · see citing works
Molecular determinants of cetuximab efficacy.
Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.100 · Cited by 234 · see citing works
Benefits from an uncertainty management intervention for African–American and Caucasian older long‐term breast cancer survivors
Mishel, M. H., Germino, B. B., Gil, K. M., Belyea, M., LaNey, I. C., Stewart, J., Porter, L., & Clayton, M. (2005) · Psycho-Oncology · doi:10.1002/pon.909 · Cited by 219 · see citing works
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer
Costanzo, E. S., Lutgendorf, S. K., Sood, A. K., Anderson, B., Sorosky, J., & Lubaroff, D. M. (2005) · Cancer · doi:10.1002/cncr.21147 · Cited by 217 · see citing works
Symptom Clusters in Breast Cancer Across 3 Phases of the Disease
Bender, C. M., Erg??n, F. S., Rosenzweig, M. Q., Cohen, S. M., & Sereika, S. M. (2005) · Cancer Nursing · doi:10.1097/00002820-200505000-00011 · Cited by 194 · see citing works
Metformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185 · see citing works
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features
Buttitta, F., Barassi, F., Fresu, G., Felicioni, L., Chella, A., Paolizzi, D., Lattanzio, G., Salvatore, S., Camplese, P. P., Rosini, S., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22143 · Cited by 180 · see citing works
Androgen biosynthetic pathways in the human prostate
Luu-The, V., Bélanger, A., & Labrie, F. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.008 · Cited by 169 · see citing works
Secondary Hormonal Therapy for Advanced Prostate Cancer
Lam, J. S., Leppert, J. T., Vemulapalli, S. N., Shvarts, O., & Belldegrun, A. S. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00034-0 · Cited by 153 · see citing works
Amplification of CDK4 and MDM2 in malignant melanoma
Muthusamy, V., Hobbs, C., Nogueira, C., Cordon‐Cardo, C., McKee, P. H., Chin, L., & Bosenberg, M. W. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20310 · Cited by 148 · see citing works
Perturbation of Rb, P53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer
Szabova, L., Yin, C., Bupp, S., Guerin, T. M., Schlomer, J. J., Householder, D. B., Baran, M. L., Yi, M., Song, Y., Sun, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3834 · Cited by 122 · see citing works
Interplay between two hormone-independent activation domains in the androgen receptor.
Callewaert, L., Van Tilborgh, N., & Claessens, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2389 · Cited by 111 · see citing works
Preliminary evaluation of the reliability and validity of the Shame and Stigma Scale in head and neck cancer
Kissane, D. W., Patel, S. G., Baser, R. E., Bell, R., Farberov, M., Ostroff, J. S., Li, Y., Singh, B., Kraus, D. H., & Shah, J. P. (2013) · Head & Neck · doi:10.1002/hed.22943 · Cited by 110 · see citing works
Effects of a Weight Loss Intervention on Body Mass, Fitness, and Inflammatory Biomarkers in Overweight or Obese Breast Cancer Survivors
Pakiz, B., Flatt, S. W., Bardwell, W. A., Rock, C. L., & Mills, P. J. (2011) · International Journal of Behavioral Medicine · doi:10.1007/s12529-010-9079-8 · Cited by 104 · see citing works
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
Debes, J. D., Comuzzi, B., Schmidt, L. J., Dehm, S. M., Culig, Z., & Tindall, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2837 · Cited by 92 · see citing works
A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
Bühler, P., Wolf, P., Gierschner, D., Schaber, I., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U., Tacke, M., Swamy, M., Schamel, W. W. A., et al. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0348-6 · Cited by 82 · see citing works
Enhancement of UVB radiation–mediated apoptosis by sanguinarine in HaCaT human immortalized keratinocytes
Reagan-Shaw, S., Breur, J., & Ahmad, N. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0250 · Cited by 64 · see citing works
Perceptions of Race/Ethnic Discrimination in Relation to Mortality Among Black Women: Results From the Black Women's Health Study
Albert, M. A. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.116 · Cited by 64 · see citing works
Surgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy
Dowdy, S. C., Stefanek, M., & Hartmann, L. C. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.04.028 · Cited by 61 · see citing works
SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis
YANG, M., XIE, X., & DING, Y. (2016) · Oncology Reports · doi:10.3892/or.2016.4545 · Cited by 30 · see citing works
Nrf2 sensitizes prostate cancer cells to radiation via decreasing basal <scp>ROS</scp> levels
Liu, M., Yao, X., Li, W., Geng, J., Yan, Y., Che, J., Xu, Y., & Zheng, J. (2015) · BioFactors · doi:10.1002/biof.1200 · Cited by 27 · see citing works

Authors: Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J.
Affiliations: American Cancer Society (US)
National Cancer Institute (US)
ORCID: Jemal, A.
Tiwari, R. C.
Ward, E.
Feuer, E. J.
Venue: CA: A Cancer Journal for Clinicians
Publisher: Wiley
Published: 2004-01-01
Volume: 54
Issue: 1
Pages: 8-29
ISSN: 0007-9235 (ISSN-L)
DOI: 10.3322/canjclin.54.1.8
OpenAlex: W2058680827
Cited by: 3,984
References: 9
Citations by year: 2025: 5 · 2024: 26 · 2023: 31 · 2022: 24 · 2021: 34 · 2020: 33 · 2019: 43 · 2018: 45 · 2017: 54 · 2016: 47 · 2015: 84 · 2014: 108 · 2013: 117 · 2012: 121
FWCI: 387.50
Type: journal article
Language: en
Open access: gold
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4261 d)
Locations: CA A Cancer Journal for Clinicians (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords: cancer incidence, cancer mortality, cancer survival rates, cancer burden, racial and ethnic disparities, African Americans, lung cancer, colon and rectum cancer, prostate cancer, breast cancer, colorectal cancer, tumor staging, cancer control, age-standardized rates
MeSH terms: Cause of Death, Humans, National Center for Health Statistics, U.S., Neoplasms, United States, Incidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer Statistics, 2004

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks